DIA-MHRA Global Summit

SESSION OVERVIEW: Regulatory science is increasingly recognized as one of the key strategic enablers of innovation, investment, and timely patient access to new medical products. This session will explore how regulatory science, collaboration, and agile approaches can help position the UK as a preferred location for product development and early launch. Speakers from the different sectors, such as MHRA, academia, industry, and the investment community will discuss the factors that influence launch and investment decisions, including scientific advice, regulatory pathways, international confidence, and the connection between approval, access, and adoption. The discussion will also examine how continued global collaboration can help translate innovation into greater patient impact.

SESSION IMPACT: Attendees will be able to take away insights about the strategic priorities of MHRA and the UK government, find out more about where regulatory science is going next in the UK, and hear the perspectives of global companies and investors as to how they make their decisions about their directions.